Mike Romanos wins promotion
Becomes chief executive of Crescendo Biologics
Romanos has been chief scientific officer of the Cambridge, UK-based company since May 2009 and has led its formation and the development of its proprietary antibody fragment technologies.
Since 2009 Crescendo has established a colony of engineered mice completely devoid of endogenous antibody polypeptides. These ‘triple knockout’ mice are believed to be unique and have the immunoglobulin heavy chain (IgH), kappa light chain and lambda light chain loci all functionally silenced by large-scale genomic deletion.
Romanos has more than 23 years’ biotech and pharma industry experience and within the last 10 years has held senior global positions leading major parts of GlaxoSmithKline Discovery.
You may also like
Research & Development
Crescendo Biologics reaches first major milestone in strategic collaboration with Takeda
Crescendo, the developer of multifunctional biologics, including targeted T-cell engagers, has achieved the first major technical milestone under the terms of its collaboration with Takeda Pharmaceutical Company
Sustainability
Building strong foundations for a resilient and planet-friendly future
Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security